Page 1

Trinity Biotech Press Release dated September 9 , 2021 Contact : Trinity Biotech plc John Gillard ( 353 ) -1-2769800 Lytham Partners , LLC Joe Diaz ( 1 ) -602-889-9700 E - mail : investorrelations@trinitybiotech.com Trinity Biotech Announces Results for Q2 , 2021 DUBLIN , Ireland ( September 9 , 2021 ) .... Trinity Biotech plc ( Nasdaq : TRIB ) , a leading developer and manufacturer of diagnostic products for the point - of - care and clinical laboratory markets , today announced results for the quarter ended June 30 , 2021 . Quarter 2 Results Total revenues for Q2 , 2021 were $ 25.8m , which compares to $ 16.0m in Q2 , 2020 , an increase of $ 9.8m and which were broken down as follows : Point - of - Care Clinical Laboratory Total 2020 Quarter 2 2021 Quarter 2 Increase US $ ' 000 US $ ' 000 % 1,267 1,958 54.5 % 14,757 23,885 61.9 % 16,024 25,843 61.3 % Point - of - Care revenues for Q2 , 2021 increased from $ 1.3m to $ 2.0m when compared to Q2 , 2020 , an increase of almost 55 % . This increase was attributable to higher HIV revenues from Africa related sales . In Q2 2020 , revenues were significantly impacted by logistical constraints caused by COVID- 19. While these constraints have eased somewhat , COVID - 19 continues to disrupt HIV testing in Africa and the associated purchase of Point - of - Care tests . Clinical Laboratory revenues increased from $ 14.8m to $ 23.9m , which represents an increase of 61.9 % compared to Q2 , 2020. The increase is mainly due to strong revenues from within our COVID- 19 related portfolio of products , with our PCR Viral Transport Media product being the most significant contributor to revenue within that portfolio . The Company noted a significant reduction in demand for new orders of VTM during early 2021 as COVID - 19 testing volumes dropped and customers utilised stockpiled product . As such Q2 2021 VTM revenue primarily derived from closing out existing orders . While the situation relating to COVID - 19 products remains very fluid , with the evolving impact of the Delta variant the Company has seen increased customer interest in VTM products over recent weeks and is taking steps to address any increase in demand that materialises . In addition to increases in revenues from products within our COVID - 19 portfolio of products , there was a significant increase in our Haemoglobins and Autoimmunity business in Q2 2021 compared to Q2 2020 as while COVID - 19 public health restrictions remained in place , in many markets these restrictions were not as severe as in Q2 2020 , thus allowing a partial return towards more normalised level of Haemoglobins and Autoimmunity testing . Gross profit for Q2 , 2021 amounted to $ 11.0m , representing a gross margin of 42.7 % . This is broadly similar to the 42.9 % achieved in Q2 , 2020 .